This is the authors' abstract. We don't add key points for this paper.
For the past two decades, targeted protein degradation (TPD) has gained ground as a novel therapeutic approach. Degraders are designed to eliminate proteins of interest by hijacking the ubiquitin-p...
No takes yet. Share an insight, caveat, or question.
Valdambrini et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: